Expeditious synthesis of ramipril: An angiotensin converting enzyme (ACE) inhibitor

被引：5
|
作者：
Malakondaiah, Golla China [1 ]
Gurav, V. M. [1 ]
Reddy, Lekkala Amarnath
Babu, Karrothu Srihari
Bhaskar, Bolugoddu Vijaya
Reddy, Padi Pratap
Bhattacharya, Apurba
Anand, Ramasamy Vijaya
机构：
[1] Dr Reddys Labs Ltd, Ctr Excellence, IPDO, Bachupalli 500072, Andhra Pradesh, India
来源：
SYNTHETIC COMMUNICATIONS | 2008年 / 38卷 / 11期
关键词：
boric acid; esterification; L-(+)-mandelic acid; ramipril; resolution;
D O I：
10.1080/00397910801989238
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
We document an efficient and cost-effective synthesis of ramipril 1 utilizing (i) an environmentally benign process for the esterification of racemic 2-aza-bicyclo-[3.3.0]-octane-3-carboxylic acid hydrochloride 2 using boric acid as a catalyst and (ii) a robust resolution process for the synthesis of 3a by means of inexpensive and recyclable L-(+)-mandelic acid as key steps.
引用
收藏
页码：1737 / 1744
页数：8
相关论文
共 50 条
  • [1] PHARMACODYNAMICS AND PHARMACOKINETICS OF RAMIPRIL (HOE 498), AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR, IN DOGS
    OMOSU, M
    YAMAZAKI, H
    HAYASHI, S
    SAKAGUCHI, T
    JAPANESE JOURNAL OF PHARMACOLOGY, 1986, 40 : P275 - P275
  • [2] Cardioprotective and nephroprotective effects of angiotensin converting enzyme inhibitor ramipril
    Napalkov, D. A.
    Golovenko, E. N.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2009, 5 (02) : 79 - 82
  • [3] Directly Cardioprotective Effects of Angiotensin Converting Enzyme (ACE) Inhibitor
    Aizaki, Yoshimi
    Yoshikawa, Ayumu
    Maruyama, Kei
    Muramatus, Toshihiro
    Nishimura, Shigeyumi
    Senbonmatsu, Takaaki
    FASEB JOURNAL, 2008, 22
  • [4] Cardioprotective effects of angiotensin converting enzyme (ACE) inhibitor through ACE signaling
    Aizaki, Yoshimi
    Yoshikawa, Ayumu
    Iida, Shinichiro
    Katoh, Makoto
    Sun, Xiao
    Maruyama, Kei
    Muramatsu, Toshihiro
    Matsumura, Makoto
    Nishimura, Shigeyuki
    Senbonmatsu, Takaaki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 109 : 262P - 262P
  • [5] PHARMACOKINETIC OPTIMIZATION OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR THERAPY
    BURNIER, M
    BIOLLAZ, J
    CLINICAL PHARMACOKINETICS, 1992, 22 (05) : 375 - 384
  • [6] Angiotensin converting enzyme (ACE)
    Khurana, Vatsala
    Goswami, Binita
    CLINICA CHIMICA ACTA, 2022, 524 : 113 - 122
  • [7] The angiotensin converting enzyme (ACE)
    Coates, D
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (06): : 769 - 773
  • [8] A RADIOIMMUNOASSAY FOR THE ANGIOTENSIN CONVERTING ENZYME-INHIBITOR RAMIPRIL AND ITS ACTIVE METABOLITE
    ECKERT, HG
    MUNSCHER, G
    OEKONOMOPULOS, R
    STRECKER, H
    URBACH, H
    WISSMANN, H
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1985, 35-2 (08): : 1251 - 1256
  • [9] THE RENIN-ANGIOTENSIN SYSTEM AND RAMIPRIL - A NEW CONVERTING-ENZYME-INHIBITOR
    VASMANT, D
    BENDER, N
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 14 : S46 - S52
  • [10] EFFECTS ON AUTONOMIC FUNCTION OF A NEW ANGIOTENSIN CONVERTING ENZYME-INHIBITOR, RAMIPRIL
    SUGIMOTO, K
    KUMAGAI, Y
    TATEISHI, T
    SEGUCHI, H
    EBIHARA, A
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 13 : S40 - S45
12345